Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

NCT07043972 | Recruiting Phase 2 DMC FDA Drug

• 2 other identifiers: GU-23025-1008
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 2

Brief Summary

The goal of this clinical trial is to learn if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with enfortumab vedotin and pembrolizumab (EVP). It will also learn about the efficacy and safety of GC in these patients. The main questions it aims to answer are:

• Does GC shrink the cancer or stop it from growing?
• What medical side effects do participants have while receiving GC? Researchers will study how GC affects survival, cancer control, and quality of life. They will also collect blood samples to look at health-related markers and cancer DNA in the blood. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Participants will:
• Receive the GC chemotherapy (gemcitabine and cisplatin) after having been treated with EVP
• Visit the clinic regularly for checkups, lab tests, and scans
• Answer questions about their health, quality of life, and daily function
• Provide blood samples for research This study may help researchers find better ways to treat advanced bladder and urinary tract cancer in the future-especially for older adults or those who have already tried other treatments.

Conditions

Urothelial Carcinoma

Keywords

phase II; locally advanced urothelial cancer; gemcitabine plus carboplatin; enfortumab vedotin plus pembrolizumab; metastatic urothelial cancer

Outcome Measures

Primary Outcomes (1)

• Best overall response (Complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) to gemcitabine plus carboplatin defined per RECIST v 1.1

  From the start of the treatment until disease progression/recurrence

  3 years

Secondary Outcomes (4)

• To evaluate progression free survival (PFS) as a function of time since study enrollment in patients receiving GC after prior exposure to EVP

  3 years

• To evaluate overall survival (OS) as a function of time since study enrollment in patients receiving GC after prior exposure to EVP

  3 years

• To evaluate the frequency and severity of toxicities attributed to GC after prior exposure to EVP

  3 years

• To evaluate the disease control rate (DCR) of gemcitabine plus carboplatin after prior exposure to EVP

  3 years

Study Arms (1)

Gemcitabine plus carboplatin

EXPERIMENTAL

Patients will be treated with gemcitabine 1,000 mg/m2 administered over 30 minutes IV on days 1 and 8, followed by carboplatin area under the curve (AUC) 5 on day 1, every 3 weeks.

Drug: Gemcitabine; Drug: Carboplatin

Interventions

Gemcitabine DRUG

IV over 30 minutes given on days 1 and 8 of a 21 day cycle

Gemcitabine plus carboplatin

Carboplatin DRUG

IV over 30 minutes given on day 1 of a 21 day cycle

Gemcitabine plus carboplatin

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have metastatic or locally advanced histologically and radiographically confirmed urothelial carcinoma
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v1.1
• Patients must have received treatment with enfortumab vedotin plus pembrolizumab in the first line setting. Study treatment may be started within 28 days of last treatment with EV-P or with continuing toxicities if considered by the Sponsor-Investigator to be safe and within the best interest of the patient.
• Age \> 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Patients must have normal organ and marrow function as defined below.
• Absolute neutrophil count \> 1,000/mm3 unless patient has constitutional neutropenia
• Platelets \> 80,000/ul
• Hemoglobin \> 8.0 g/dL
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 x ULN or \<3.5 x upper limit of normal (ULN) if liver metastases
• Creatinine Clearance \>20 mL/min
• Ability to understand and willingness to sign a written informed consent and HIPAA consent document
• Optional: Archival tumor biospecimen, when available, must be procured for correlative evaluation. If tumor tissue is not available or accessible despite good faith efforts, patient may still be treated on study. Formalin fixed paraffin embedded (FFPE) tissue block(s) or at least 15 unbaked, unstained slides are required. Tissue samples taken from a metastatic lesion prior to the start of screening are acceptable.

You may not qualify if:

• Patients who have had systemic treatment including EV-P or radiotherapy within 2 weeks prior to entering the study
• Patients who have had systemic treatment including EV-P or radiotherapy within 2 weeks prior to entering the study
• Patients who have received more than one line of prior therapy or prior platinum-based chemotherapy for locally advanced or metastatic urothelial carcinoma (neoadjuvant platinum-based therapy including cisplatin is allowed)
• Patients who have not recovered from adverse events to less than Grade 2 secondary to agents administered more than 2 weeks prior to treatment initiation.
• Patients may not be receiving any other investigational agents
• Patients with uncontrolled and untreated CNS metastases:
• Prior radiation to central nervous system (CNS) metastases is permitted
• Prior history of CNS disease that has responded to previous systemic therapy is permitted only if no recurrence
• Patient should not have leptomeningeal disease
• CNS metastases have been clinically stable for at least 6 weeks prior to screening and baseline scans show no evidence of new or enlarged metastases
• Uncontrolled intercurrent illness including, but not limited to ongoing or active untreated infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit adherence with study requirements
• Subjects with a history of another invasive malignancy within 3 years before the first dose of study drug that cannot be watched and requires tumor- directed treatment, or any evidence of residual disease from a previously diagnosed malignancy that cannot be watched and requires treatment (adjuvant hormonal therapy for breast cancer is allowed)
• Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of chemotherapy (routine antimicrobial prophylaxis is permitted)
• Pregnant or breast feeding.

Sponsors & Collaborators

• Fox Chase Cancer Center: lead

Study Sites (2)

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

RECRUITING

Temple University Hospital at Broad Street

Philadelphia, Pennsylvania, 19140, United States

RECRUITING

MeSH Terms

Conditions

Carcinoma, Transitional Cell

Interventions

Gemcitabine; Carboplatin

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Coordination Complexes; Organic Chemicals

Study Officials

• Daniel Geynisman, MD

  Fox Chase Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Daniel Geynisman, MD

CONTACT

(888) 369-2427; Daniel.Geynisman@fccc.edu

Ryan Romasko, MBA

CONTACT

(888) 369-2427; protocoldev@fccc.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 26, 2025
• First Posted: June 29, 2025
• Study Start: July 9, 2025
• Primary Completion (Estimated): January 1, 2030
• Study Completion (Estimated): January 1, 2031
• Last Updated: July 20, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)